pyridoxine has been researched along with Hyperhomocysteinemia in 73 studies
4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source
vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).
Hyperhomocysteinemia: Condition in which the plasma levels of homocysteine and related metabolites are elevated (
| Excerpt | Relevance | Reference |
|---|---|---|
| "A subgroup of schizophrenic patients with hyperhomocysteinemia might benefit from the simple addition of B vitamins." | 9.12 | Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. ( Babushkin, I; Belmaker, RH; Bersudsky, Y; Levine, J; Osher, Y; Ruderman, V; Sela, BA; Shumaico, O; Stahl, Z, 2006) |
| "The Vitamins and Thrombosis (VITRO) study investigated the effect of homocysteine lowering by daily supplementation of B vitamins on the risk reduction of deep vein thrombosis (DVT) and pulmonary embolism (PE)." | 9.12 | Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. ( Blom, HJ; Bos, GM; Cattaneo, M; den Heijer, M; Eichinger, S; Gerrits, WB; Rosendaal, FR; Willems, HP, 2007) |
| "Fasting and post-methionine load hyperhomocysteinemia are independent risk factors for vascular disease that are common in chronic renal failure." | 9.10 | Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure. ( Chambers, ST; Dellow, WJ; George, PM; Lever, M; McGregor, DO; Robson, RA, 2002) |
| "The effectiveness of intravenous folinic acid or intravenous folic acid for the treatment of hyperhomocysteinemia of hemodialysis patients is unknown." | 9.09 | Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients. ( Apsner, R; Bieglmayer, C; Buchmayer, H; Födinger, M; Hagen, W; Hauser, AC; Hörl, WH; Ignatescu, M; Köller, E; Papagiannopoulos, M; Rehak, PH; Sunder-Plassmann, G, 2001) |
| "Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy." | 9.09 | Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. ( Chadefaux-Vekemans, B; Drüeke, T; Jungers, P; Massy, ZA; Touam, M; Zingraff, J, 1999) |
| "Hyperhomocysteinemia has been commonly found among heart transplant recipients (average prevalence 51% to 76%)." | 8.81 | Hyperhomocysteinemia and transplant coronary artery disease. ( Caldera, A; Dec, GW, 2002) |
| "Although there is insufficient evidence to recommend the screening or management of hyperhomocysteinemia at present (grade C recommendation), adherence to recommended daily allowance of dietary sources of folate and vitamins B12 and B6 should be encouraged." | 8.80 | Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care. ( Booth, GL; Wang, EE, 2000) |
| "Homocystinuria (HCU) due to cystathionine beta-synthase (CBS) deficiency leads to severe hyperhomocysteinemia (HHcy)." | 8.80 | Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy. ( Boers, GH; Naughten, ER; Wilcken, B; Wilcken, DE; Yap, S, 2000) |
| " Fasting and post-methionine loading hyperhomocysteinemia can be normalized in virtually all renal transplant patients by a combination of folic acid (5 mg/d), vitamin B6 (50 mg/d) and vitamin B12 (0." | 8.80 | Hyperhomocysteinemia in organ transplantation. ( Floth, A; Födinger, M; Sunder-Plassmann, G, 2000) |
| "In recent years research was done to elucidate the relation between an increased homocysteine concentration and arterial as well as venous thrombosis." | 8.80 | [Hyperhomocysteinemia as a risk factor for venous thrombosis]. ( Blom, HJ; Bos, GM; den Heijer, M; Gerrits, WB; Rosendaal, FR; Willems, HP, 1999) |
| "Hyperhomocysteinemia is a risk factor for atherosclerosis that is common in chronic renal failure (CRF), but its cause is unknown." | 7.71 | Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. ( Chambers, ST; Dellow, WJ; George, PM; Lever, M; McGregor, DO; Robson, RA, 2001) |
| "Hyperhomocysteinemia is a cardiovascular disease (CVD) risk factor." | 7.71 | Influence of vitamin-optimized plasma homocysteine cutoff values on the prevalence of hyperhomocysteinemia in healthy adults. ( Dijck-Brouwer, DA; Fokkema, MR; Muskiet, FA; van Doormaal, JJ; Weijer, JM, 2001) |
| "Hyperhomocysteinemia is more prevalent and intense in HD patients compared with those on PD." | 7.70 | Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. ( Arheart, K; Dennis, VW; Gupta, A; Jacobsen, DW; Moustapha, A; Robinson, K; Schreiber, MJ, 1999) |
| "The effect of homocysteine-lowering treatment on thrombin generation was investigated in 17 subjects with hyperhomocysteinemia (aged 22-60 years), 11 of whom had symptomatic atherosclerotic vascular disease." | 7.70 | Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation. ( Domagala, TB; Jankowski, M; Szczeklik, A; Undas, A, 1999) |
| "Mild hyperhomocysteinemia is an independent risk factor for increased carotid artery wall thickness and plaque formation in a general population." | 7.70 | Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS) ( Beilby, JP; Hung, J; McQuillan, BM; Nidorf, M; Thompson, PL, 1999) |
| "Moreover, mild hyperhomocysteinemia has been shown to be associated with a 2 to 4-fold increased relative risk for coronary artery disease, cerebrovascular disease, and peripheral arterial occlusive disease." | 6.40 | [Hyperhomocysteinemia: a risk factor for arterial and venous thrombosis]. ( Solenthaler, M; Wuillemin, WA, 1999) |
| "A subgroup of schizophrenic patients with hyperhomocysteinemia might benefit from the simple addition of B vitamins." | 5.12 | Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. ( Babushkin, I; Belmaker, RH; Bersudsky, Y; Levine, J; Osher, Y; Ruderman, V; Sela, BA; Shumaico, O; Stahl, Z, 2006) |
| "The Vitamins and Thrombosis (VITRO) study investigated the effect of homocysteine lowering by daily supplementation of B vitamins on the risk reduction of deep vein thrombosis (DVT) and pulmonary embolism (PE)." | 5.12 | Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. ( Blom, HJ; Bos, GM; Cattaneo, M; den Heijer, M; Eichinger, S; Gerrits, WB; Rosendaal, FR; Willems, HP, 2007) |
| "Fasting and post-methionine load hyperhomocysteinemia are independent risk factors for vascular disease that are common in chronic renal failure." | 5.10 | Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure. ( Chambers, ST; Dellow, WJ; George, PM; Lever, M; McGregor, DO; Robson, RA, 2002) |
| "Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy." | 5.09 | Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. ( Chadefaux-Vekemans, B; Drüeke, T; Jungers, P; Massy, ZA; Touam, M; Zingraff, J, 1999) |
| "The effectiveness of intravenous folinic acid or intravenous folic acid for the treatment of hyperhomocysteinemia of hemodialysis patients is unknown." | 5.09 | Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients. ( Apsner, R; Bieglmayer, C; Buchmayer, H; Födinger, M; Hagen, W; Hauser, AC; Hörl, WH; Ignatescu, M; Köller, E; Papagiannopoulos, M; Rehak, PH; Sunder-Plassmann, G, 2001) |
| "Hyperhomocysteinemia occurs in nearly 100% of patients with end-stage renal disease (ESRD) and is associated with increased morbidity and mortality." | 5.09 | Homocysteine lowering effect of different multivitamin preparations in patients with end-stage renal disease. ( Bosselmann, KP; Dierkes, J; Domröse, U; Luley, C; Neumann, KH, 2001) |
| "Hyperhomocysteinemia has been commonly found among heart transplant recipients (average prevalence 51% to 76%)." | 4.81 | Hyperhomocysteinemia and transplant coronary artery disease. ( Caldera, A; Dec, GW, 2002) |
| " Fasting and post-methionine loading hyperhomocysteinemia can be normalized in virtually all renal transplant patients by a combination of folic acid (5 mg/d), vitamin B6 (50 mg/d) and vitamin B12 (0." | 4.80 | Hyperhomocysteinemia in organ transplantation. ( Floth, A; Födinger, M; Sunder-Plassmann, G, 2000) |
| "Although there is insufficient evidence to recommend the screening or management of hyperhomocysteinemia at present (grade C recommendation), adherence to recommended daily allowance of dietary sources of folate and vitamins B12 and B6 should be encouraged." | 4.80 | Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care. ( Booth, GL; Wang, EE, 2000) |
| "Hyperhomocysteinemia refers to an elevated circulating level of the sulfur-containing amino acid homocysteine and has been shown to be a risk factor for vascular disease in the general population." | 4.80 | Homocysteine and renal disease. ( Robinson, K; van Guldener, C, 2000) |
| "Homocystinuria (HCU) due to cystathionine beta-synthase (CBS) deficiency leads to severe hyperhomocysteinemia (HHcy)." | 4.80 | Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy. ( Boers, GH; Naughten, ER; Wilcken, B; Wilcken, DE; Yap, S, 2000) |
| " In this article we review the main theories of atherosclerosis which take into account the proteins, namely homocysteine, homocysteine metabolism, the cause that may be responsible for high levels of homocysteinemia, the pathophysiologic mechanisms of vascular lesion induced by hyperhomocysteinemia, the clinical evidence that homocysteinemia constitutes a vascular risk factor and finally, the evidence that it is possible to control homocysteinemia with supplementation of co-factors of homocysteine metabolism, namely vitamin B6, B12 or folic acid." | 4.80 | [Homocysteinemia and vascular disease--a new risk factor is born]. ( Luís, AS; Reis, RP, 1999) |
| "In recent years research was done to elucidate the relation between an increased homocysteine concentration and arterial as well as venous thrombosis." | 4.80 | [Hyperhomocysteinemia as a risk factor for venous thrombosis]. ( Blom, HJ; Bos, GM; den Heijer, M; Gerrits, WB; Rosendaal, FR; Willems, HP, 1999) |
| " Hyperhomocysteinemia was defined as fasting total Hcy above 12 micromol/L and/or post-methionine load concentrations above 38 micromol/L." | 3.74 | Drug-induced pertubation of the aminothiol redox-status in patients with epilepsy: improvement by B-vitamins. ( Apeland, T; Frøyland, ES; Kristensen, O; Mansoor, MA; Strandjord, RE, 2008) |
| "The concept of a short, high-dose induction therapy with intravenous folic acid, pyridoxine, cyanocobalamin, and a subsequent low-dose maintenance regimen is effective in the treatment of hyperhomocysteinemia in patients with ESRD." | 3.72 | Intravenous treatment of hyperhomocysteinemia in patients on chronic hemodialysis--a pilot study. ( Gerhardt, T; Klehr, HU; Look, M; Pöge, U; Sauerbruch, T; Woitas, RP, 2004) |
| "Using an atherogenic diet that produces both hyperhomocysteinemia and hypercholesterolemia, we tested the hypothesis that dietary supplementation with B vitamins (folic acid, vitamin B(12), and vitamin B(6)) would prevent hyperhomocysteinemia, vascular dysfunction, and atherosclerotic lesions in monkeys." | 3.71 | Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys. ( Heistad, DD; Lentz, SR; Malinow, MR; Piegors, DJ, 2001) |
| "Hyperhomocysteinemia is a cardiovascular disease (CVD) risk factor." | 3.71 | Influence of vitamin-optimized plasma homocysteine cutoff values on the prevalence of hyperhomocysteinemia in healthy adults. ( Dijck-Brouwer, DA; Fokkema, MR; Muskiet, FA; van Doormaal, JJ; Weijer, JM, 2001) |
| "Hyperhomocysteinemia is a risk factor for atherosclerosis that is common in chronic renal failure (CRF), but its cause is unknown." | 3.71 | Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations. ( Chambers, ST; Dellow, WJ; George, PM; Lever, M; McGregor, DO; Robson, RA, 2001) |
| "Hyperhomocysteinemia is more prevalent and intense in HD patients compared with those on PD." | 3.70 | Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. ( Arheart, K; Dennis, VW; Gupta, A; Jacobsen, DW; Moustapha, A; Robinson, K; Schreiber, MJ, 1999) |
| "Mild hyperhomocysteinemia is an independent risk factor for increased carotid artery wall thickness and plaque formation in a general population." | 3.70 | Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS) ( Beilby, JP; Hung, J; McQuillan, BM; Nidorf, M; Thompson, PL, 1999) |
| "The aim of this study was to investigate a possible association among the thermolabile polymorphism, nucleotide 677 cytosine to thymidine point mutation (677 C-->T) of the methylenetetrahydrofolate reductase (MTHFR) gene, hyperhomocysteinemia, serum folate, vitamins B12 and B6, and stroke in children." | 3.70 | Children with stroke: polymorphism of the MTHFR gene, mild hyperhomocysteinemia, and vitamin status. ( Artuch, R; Campistol, J; Cardo, E; Colomé, C; Monrós, E; Pineda, M; Vilaseca, MA, 2000) |
| "Chronic alcohol consumption produces hyperhomocysteinemia by a mechanism that is related to interference with one-carbon metabolism, and not through vitamin depletion." | 3.70 | Effect of chronic alcohol consumption on total plasma homocysteine level in rats. ( Bagley, PJ; Choi, SW; Kim, YI; Mason, JB; Russell, RM; Seitz, HK; Selhub, J; Stickel, F, 2000) |
| "The effect of homocysteine-lowering treatment on thrombin generation was investigated in 17 subjects with hyperhomocysteinemia (aged 22-60 years), 11 of whom had symptomatic atherosclerotic vascular disease." | 3.70 | Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation. ( Domagala, TB; Jankowski, M; Szczeklik, A; Undas, A, 1999) |
| "Analysis of metabolites additional to homocysteine levels may help to understand different results in evaluation of atherosclerotic risk of hyperhomocysteinemia in chronic renal failure." | 3.70 | [Homocysteine and its metabolites in chronic renal insufficiency and the effect of a vitamin replacement]. ( Graefe, U; Henning, BF; Tepel, M; Zidek, W, 2000) |
| "In study II, 41 patients with type 2 diabetes and mild hyperhomocysteinaemia were analysed after 6 months treatment with 5 mg of folic acid or placebo." | 2.72 | No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk. ( Brouwer, CB; Rauwerda, JA; Smulders, YM; Spoelstra-de Man, AM; Stehouwer, CD; Teerlink, T, 2006) |
| "Causes of hyperhomocysteinemia are hereditary heterozygous or, in very rare cases, homozygous defects, and quite frequently a lack of the coenzymes B6 and B12 and the cosubstrate folate." | 2.41 | Homocysteine--relevant for atherogenesis? ( Kircher, T; Sinzinger, H, 2000) |
| "Moreover, mild hyperhomocysteinemia has been shown to be associated with a 2 to 4-fold increased relative risk for coronary artery disease, cerebrovascular disease, and peripheral arterial occlusive disease." | 2.40 | [Hyperhomocysteinemia: a risk factor for arterial and venous thrombosis]. ( Solenthaler, M; Wuillemin, WA, 1999) |
| "Homocystinuria is an uncommon genetic disease characterized by a marked increase of serum homocysteine (HCY), an intermediate of methionine metabolism." | 2.40 | [Homocysteine and cardiovascular risk]. ( Chapelle, JP; Gielen, J; Lutteri, L, 1999) |
| "Pyridoxine has no additional value." | 1.31 | The effect of different treatment regimens in reducing fasting and postmethionine-load homocysteine concentrations. ( Banga, JD; Biesma, DH; Duran, M; Faber, JA; Haas, FJ; Meuwissen, OJ; van der Griend, R, 2000) |
| "Valproic acid treatment, although also associated with hyperhomocysteinaemia, only shows a lowering effect on vitamin B6 levels, which seems to be independent of the MTHFR genotype." | 1.31 | Anti-epileptic drug treatment in children: hyperhomocysteinaemia, B-vitamins and the 677C-->T mutation of the methylenetetrahydrofolate reductase gene. ( Artuch, R; Cardo, E; Colomé, C; Farré, C; Monrós, E; Pineda, M; Valls, C; Vilaseca, MA, 2000) |
| "Further studies are needed to correlate treatment of hyperhomocysteinemia with clinical endpoints, such as the time to development of transplant vasculopathy and long-term survival, and to define the most appropriate targets for therapy." | 1.31 | Effective treatment of hyperhomocysteinemia in heart transplant recipients with and without renal failure. ( Abel, JG; Cook, RC; Frohlich, JJ; Gao, M; Ignaszewski, AP; Kingsbury, K; Parker, S, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 24 (32.88) | 18.2507 |
| 2000's | 46 (63.01) | 29.6817 |
| 2010's | 2 (2.74) | 24.3611 |
| 2020's | 1 (1.37) | 2.80 |
| Authors | Studies |
|---|---|
| Ventura, P | 1 |
| Sardh, E | 1 |
| Longo, N | 1 |
| Balwani, M | 1 |
| Plutzky, J | 1 |
| Gouya, L | 1 |
| Phillips, J | 1 |
| Rhyee, S | 1 |
| Fanelli, MJ | 1 |
| Sweetser, MT | 1 |
| Petrides, PE | 1 |
| Mayengbam, S | 1 |
| Raposo, S | 1 |
| Aliani, M | 1 |
| House, JD | 1 |
| Apeland, T | 1 |
| Frøyland, ES | 1 |
| Kristensen, O | 2 |
| Strandjord, RE | 1 |
| Mansoor, MA | 2 |
| Novy, J | 1 |
| Ballhausen, D | 1 |
| Bonafé, L | 1 |
| Cairoli, A | 1 |
| Angelillo-Scherrer, A | 1 |
| Bachmann, C | 1 |
| Michel, P | 1 |
| O'Donnell, J | 1 |
| Perry, DJ | 1 |
| Caldera, A | 1 |
| Dec, GW | 1 |
| Kammerer, S | 1 |
| Marcucci, R | 1 |
| Zanazzi, M | 1 |
| Bertoni, E | 1 |
| Rosati, A | 1 |
| Fedi, S | 1 |
| Lenti, M | 1 |
| Prisco, D | 1 |
| Castellani, S | 1 |
| Abbate, R | 1 |
| Salvadori, M | 1 |
| Jonasson, TF | 1 |
| Hedner, T | 1 |
| Hultberg, B | 2 |
| Ohlin, H | 2 |
| Stehouwer, CD | 7 |
| van Guldener, C | 2 |
| Pöge, U | 1 |
| Look, M | 1 |
| Gerhardt, T | 1 |
| Klehr, HU | 1 |
| Sauerbruch, T | 1 |
| Woitas, RP | 1 |
| Jonasson, T | 1 |
| Ohlin, AK | 1 |
| Gottsäter, A | 1 |
| Jamison, RL | 1 |
| Hartigan, P | 1 |
| Gaziano, JM | 1 |
| Fortmann, SP | 2 |
| Goldfarb, DS | 1 |
| Haroldson, JA | 1 |
| Kaufman, J | 1 |
| Lavori, P | 1 |
| McCully, KS | 1 |
| Robinson, K | 3 |
| Levine, J | 1 |
| Stahl, Z | 1 |
| Sela, BA | 1 |
| Ruderman, V | 1 |
| Shumaico, O | 1 |
| Babushkin, I | 1 |
| Osher, Y | 1 |
| Bersudsky, Y | 1 |
| Belmaker, RH | 1 |
| Spoelstra-de Man, AM | 1 |
| Teerlink, T | 1 |
| Brouwer, CB | 1 |
| Rauwerda, JA | 6 |
| Smulders, YM | 1 |
| den Heijer, M | 3 |
| Willems, HP | 3 |
| Blom, HJ | 2 |
| Gerrits, WB | 2 |
| Cattaneo, M | 2 |
| Eichinger, S | 1 |
| Rosendaal, FR | 2 |
| Bos, GM | 3 |
| Sawka, AM | 1 |
| Ray, JG | 1 |
| Yi, Q | 1 |
| Josse, RG | 1 |
| Lonn, E | 1 |
| Clarke, R | 1 |
| Collins, R | 1 |
| Moustapha, A | 1 |
| Gupta, A | 1 |
| Arheart, K | 1 |
| Jacobsen, DW | 1 |
| Schreiber, MJ | 1 |
| Dennis, VW | 1 |
| van der Griend, R | 2 |
| Haas, FJ | 2 |
| Biesma, DH | 2 |
| Duran, M | 2 |
| Meuwissen, OJ | 2 |
| Banga, JD | 2 |
| McQuillan, BM | 1 |
| Beilby, JP | 1 |
| Nidorf, M | 1 |
| Thompson, PL | 1 |
| Hung, J | 1 |
| de Jong, SC | 4 |
| van den Berg, M | 3 |
| Kostense, PJ | 1 |
| Alders, D | 1 |
| Jakobs, C | 2 |
| Pals, G | 1 |
| Lubbers, MF | 1 |
| Aarnoudse, JG | 1 |
| van Doormaal, JJ | 2 |
| Genest, J | 1 |
| Hervig, T | 1 |
| Bates, CJ | 1 |
| Pentieva, K | 1 |
| Vefring, H | 1 |
| Osland, A | 1 |
| Berge, T | 1 |
| Drabløs, PA | 1 |
| Hetland, O | 1 |
| Rolfsen, S | 1 |
| Turner, SL | 1 |
| Bechtel, GA | 1 |
| Reis, RP | 1 |
| Luís, AS | 1 |
| Dierkes, J | 2 |
| Westphal, S | 1 |
| Luley, C | 2 |
| Lutteri, L | 1 |
| Chapelle, JP | 1 |
| Gielen, J | 1 |
| Geurts, TW | 1 |
| Bouter, LM | 1 |
| Wuillemin, WA | 1 |
| Solenthaler, M | 1 |
| Constans, J | 2 |
| Undas, A | 1 |
| Domagala, TB | 1 |
| Jankowski, M | 1 |
| Szczeklik, A | 1 |
| Weiss, N | 1 |
| Pietrzik, K | 1 |
| Keller, C | 1 |
| Li, W | 1 |
| Zheng, T | 1 |
| Wang, J | 1 |
| Altura, BT | 1 |
| Altura, BM | 1 |
| Touam, M | 1 |
| Zingraff, J | 1 |
| Jungers, P | 1 |
| Chadefaux-Vekemans, B | 1 |
| Drüeke, T | 1 |
| Massy, ZA | 1 |
| Blann, AD | 1 |
| Resplandy, F | 1 |
| Parrot, F | 1 |
| Renard, M | 1 |
| Seigneur, M | 1 |
| Guérin, V | 1 |
| Boisseau, M | 1 |
| Conri, C | 1 |
| Chao, CL | 1 |
| Chien, KL | 1 |
| Lee, YT | 1 |
| Bostom, AG | 1 |
| Garber, C | 1 |
| Vermeulen, EG | 2 |
| Twisk, JW | 3 |
| Mackaay, AJ | 1 |
| van Campen, CM | 1 |
| Visser, FC | 1 |
| Jakobs, CA | 1 |
| Bulterjis, EJ | 1 |
| Erix, P | 1 |
| Witjes, RJ | 1 |
| Stickel, F | 1 |
| Choi, SW | 1 |
| Kim, YI | 1 |
| Bagley, PJ | 1 |
| Seitz, HK | 1 |
| Russell, RM | 1 |
| Selhub, J | 1 |
| Mason, JB | 1 |
| Sunder-Plassmann, G | 4 |
| Floth, A | 1 |
| Födinger, M | 3 |
| Cardo, E | 2 |
| Monrós, E | 2 |
| Colomé, C | 2 |
| Artuch, R | 2 |
| Campistol, J | 1 |
| Pineda, M | 2 |
| Vilaseca, MA | 2 |
| Booth, GL | 1 |
| Wang, EE | 1 |
| Kircher, T | 1 |
| Sinzinger, H | 1 |
| Faber, JA | 1 |
| Boers, GH | 2 |
| Yap, S | 1 |
| Naughten, ER | 1 |
| Wilcken, B | 1 |
| Wilcken, DE | 1 |
| Henning, BF | 1 |
| Tepel, M | 1 |
| Graefe, U | 1 |
| Zidek, W | 1 |
| Diaz-Arrastia, R | 1 |
| Winkelmayer, WC | 1 |
| Ignatescu, MC | 1 |
| Födiger, M | 1 |
| Kletzmayr, J | 1 |
| Bieglmayer, C | 2 |
| Hörl, WH | 2 |
| Lentz, SR | 1 |
| Piegors, DJ | 1 |
| Malinow, MR | 1 |
| Heistad, DD | 1 |
| Suliman, ME | 1 |
| Filho, JC | 1 |
| Bárány, P | 1 |
| Anderstam, B | 1 |
| Lindholm, B | 1 |
| Bergström, J | 1 |
| Hofmann, MA | 1 |
| Lalla, E | 1 |
| Lu, Y | 1 |
| Gleason, MR | 1 |
| Wolf, BM | 1 |
| Tanji, N | 1 |
| Ferran, LJ | 1 |
| Kohl, B | 1 |
| Rao, V | 1 |
| Kisiel, W | 1 |
| Stern, DM | 1 |
| Schmidt, AM | 1 |
| Cook, RC | 1 |
| Parker, S | 1 |
| Kingsbury, K | 1 |
| Frohlich, JJ | 1 |
| Abel, JG | 1 |
| Gao, M | 1 |
| Ignaszewski, AP | 1 |
| Hauser, AC | 1 |
| Hagen, W | 1 |
| Rehak, PH | 1 |
| Buchmayer, H | 1 |
| Papagiannopoulos, M | 1 |
| Apsner, R | 1 |
| Köller, E | 1 |
| Ignatescu, M | 1 |
| Farré, C | 1 |
| Valls, C | 1 |
| Domröse, U | 1 |
| Bosselmann, KP | 1 |
| Neumann, KH | 1 |
| Fokkema, MR | 1 |
| Weijer, JM | 1 |
| Dijck-Brouwer, DA | 1 |
| Muskiet, FA | 1 |
| McGregor, DO | 2 |
| Dellow, WJ | 2 |
| Lever, M | 2 |
| George, PM | 2 |
| Robson, RA | 2 |
| Chambers, ST | 2 |
| Kutschka, I | 1 |
| Pethig, K | 1 |
| Strüber, M | 1 |
| Dieterich, C | 1 |
| Harringer, W | 1 |
| Haverich, A | 1 |
| Miller, JW | 1 |
| Wrone, EM | 1 |
| Zehnder, JL | 1 |
| Hornberger, JM | 1 |
| McCann, LM | 1 |
| Coplon, NS | 1 |
| van Dijk, RA | 1 |
| Steyn, M | 1 |
| Schnyder, G | 1 |
| Roffi, M | 1 |
| Pin, R | 1 |
| Flammer, Y | 1 |
| Lange, H | 1 |
| Eberli, FR | 1 |
| Meier, B | 1 |
| Turi, ZG | 1 |
| Hess, OM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Homocysteine Lowering by B Vitamins and the Secondary Prevention of Deep-Vein Thrombosis and Pulmonary Embolism. A Randomized, Placebo-Controlled, Double Blind Trial.[NCT00314990] | 620 participants | Interventional | 1996-01-31 | Completed | |||
| HOPE-2 Study (Heart Outcomes Prevention Evaluation-2 Study)[NCT00106886] | Phase 4 | 5,000 participants | Interventional | 1999-12-31 | Active, not recruiting | ||
| A Single-Center, Open-Label Study to Assess the Effects of the Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis Evaluated With the PASI, PGA and DLQI[NCT01704599] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to side effect and poor clinical outcome) | ||
| 5-methyltetrahydrofolate Survival and Inflammation in ESRD Patients[NCT00626223] | 341 participants (Actual) | Interventional | 1998-01-31 | Completed | |||
| Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria[NCT00283387] | Phase 2 | 15 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change in EKG ( normalize, unchanged, became abnormal) when homocysteine (Hcy) increased or decreased from week 16 on adalimumab to week 28 on adalimumab plus folic acid, vitamins B6 and B12 in adault psoriasis patients ages 18-65 with moderate to severe plaque psoriasis. (NCT01704599)
Timeframe: Week 16 to Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| normalize when Hcy increased | unchanged when Hcy decreased | became abnormal when Hcy decreased | |
| Humira Then Humira Plus 3 B Vitamins | 1 | 2 | 1 |
Change in CBC parameter: white blood count or hemoglobin or hematocrit ( as measured week 16 on adalimumab and at week 28 after 12 more weeks on adalimuamb , folic acid, B6 and B12) in adults ages 18-65 with moderate to severe plaque psoriasis. (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| WBC increased | WBC unchanged | WBC decreased | Hemoglobin/Hematocrit increased | Hemoglobin/Hematocrit unchanged | Hemoglobin/Hematocrit decreased | |
| Humira Then Humira Plus 3 B Vitamins | 3 | 0 | 2 | 3 | 0 | 2 |
"Worsening psoriasis or development or worsening of measured condition or new pathology not seen by week 16 but developed at weeks 28 or first discoved by telephone call day 70 post study:~AE Humira only" (NCT01704599)
Timeframe: After Week 16 of study
| Intervention | participants (Number) | ||
|---|---|---|---|
| No Adverse Event after Week 16 | Adverse Event Weeks 16-28 | Adverse event by Day 70 call after Week 28 | |
| Humira Then Humira Plus 3 B Vitamins | 2 | 4 | 1 |
A serious adverse event is hosptalization or death or pathology leading to early termination of a participant from the study. This was to be reported at anytime during the 28 week study of adult patients ages 18-65 with moderate to severe plaque psoriasis though categorized by Week 16 (on adalimumab alone, by Week 28 (on adalimuamb plus 3 B vitaminsand by day 70 post Week 28. (NCT01704599)
Timeframe: By Week 16, by Week 28 and by Day 70 post Week 28.
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| No SAE | SAE by Week 16 | SAE by Week 28 | SAE by Day 70 afterWeek 28 | |
| Humira Then Humira Plus 3 B Vitamins | 7 | 1 | 0 | 0 |
An electrocardiogram (EKG) is used to evaluate the electrical activity of the heart by converting this activity into line tracings on paper.. Electrodes (small, plastic patches) are placed at certain locations on the chest, arms, and legs. When the electrodes are connected to an EKG machine by lead wires, the electrical activity of the heart is measured, interpreted, and printed out for the doctor's information and further interpretation. This test was to be administered to adults age 18 or older with moderate to severe plaque psoriasis patients at week 0, 16 and week 28 of this study. (NCT01704599)
Timeframe: Week 16 and then Week 28 after another 12 weeks on Humira plus vitamins and if early termination
| Intervention | participants (Number) | ||
|---|---|---|---|
| Normalizing | Unchanged | Newly abnormal | |
| Humira Then Humira Plus 3 B Vitamins | 1 | 4 | 1 |
Height is the distance from the bottom (soles of feet ) to the top (top of head) of a person when that person is standing in this study using ruler in inches.Participants measured were adults age 18 or older with moderate to severe plaque psoriasis. (NCT01704599)
Timeframe: Week 0 at Start of Adalimumab
| Intervention | participants (Number) | |
|---|---|---|
| Measured | Not measured | |
| Humira Then Humira Plus 3 B Vitamins | 8 | 0 |
Number of participants with a category change in Physician static Global Assessment (sPGA): 7 point score from 0 (clear) to 6 measuring amount of surface covered and plaque qualities: thickness & erythema plus scaling. Dynamic score compares baseline with either improvement/ worsening of the same factors measured in the sPGA using the 0-6 scoring range but focused on change. sPGA at weeks 16 AND 28. dynamic PGA to be categoically measured at.weeks16 and 28. (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Unchanged | Worsened | |
| Humira Then Humira Plus 3 B Vitamins | 3 | 1 | 3 |
DLQI is 10 questions examining impact of skin disease on quality of life: (1) symptoms & feelings (2) daily activities (3) leisure (4) work & school (5) personal relationship (6) treatment. To be administered to adults over 18 years with moderate to severe plaque psoriasis at week 0 (no systemic psoriasis medication);. weeks 16 ( after 16 weeks of adalimumab) and week 28 (after 16 weeks adalimumab then 12 weeks of adalimumab plus daily 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg B12). (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Unchanged | Worsened | |
| Humira Then Humira Plus 3 B Vitamins | 3 | 3 | 1 |
Serum folic acid level in adults ages 18 and older with mild to moderate plaque psoriasis measured at week 16 after 16 weeks adalimumab and at week 28 after 16 weeks adalimumab plus 12 weeks of adalimumab and daily 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg B12. (NCT01704599)
Timeframe: Weeks 16 and 28
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Increased | Unchanged | Decreased | Not evaluable (if >20 ng/ml only stated as such) | |
| Humira Then Humira Plus 3 B Vitamins | 3 | 0 | 0 | 2 |
Adult particpants ages 18 or older with moderate to severe plaque psoriasis were to have serum VEGF measured at week 0 on no systemic psoriasis medication then at both weeks 16 on adalimumab and at week 28 on adalimumab plus folic acid, B6 and Vitamin B12. Subjects raniked by BMI week 0 low to high (NCT01704599)
Timeframe: At Screening visit, Week 16 on Humira, after another 12 weeks on Humira plus vitamins and if early termination
| Intervention | participants (Number) | ||
|---|---|---|---|
| Increased | Unchanged | Decreased | |
| Humira Then Humira Plus 3 B Vitamins | 4 | 0 | 1 |
Adult participants 18 years or older with moderate to severe plaque psoriasis were to have serum B12 levels measures Weeks 0 (on no systemic psoriasis medication), 16 (on adalimumab) and week 28 (on adalimumab plus daily 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg B12. (NCT01704599)
Timeframe: At Week 16 and Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Increased | Unchanged | Worsened | |
| Humira Then Humira Plus 3 B Vitamins | 5 | 0 | 0 |
Using a thermometer for body temperature on degrees Fahrenheit. Participants to be measured were adults 18 years or older with moderate to severe plaque psoriasis with temperature to be measured at week 16 16 weeks of adalimumab and week 28 after 16 weeks of adalimumab then 12 weeks of adalimumab plus 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg of B12. (NCT01704599)
Timeframe: Weeks 16 and 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| increased | unchanged | decreased | |
| Humira Then Humira Plus 3 B Vitamins | 2 | 2 | 1 |
Adult participants age 18 years or older with moderate to severe plaque psoriasis with serum IgG antibodies against Helicobacter pylori bacteria using commercial ELISA assay during the 28 week study. (NCT01704599)
Timeframe: Week 28 after 16 weeks of Adalimumab then 12 of Adalimumab-Vitamins
| Intervention | participants (Number) | |
|---|---|---|
| Elevated | Normal | |
| Humira Then Humira Plus 3 B Vitamins | 2 | 6 |
Weight is how heavy a participant is. Weight in pounds of each study adult participant age 18-65 years with moderate to severe plaque psoriasis measured at weeks 16 and compared to week 28 of study. (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Increased | Unchanged | Decreased | |
| Humira Then Humira Plus 3 B Vitamins | 2 | 0 | 5 |
Blood pressure is the force the heart exerts against the walls of arteries as it pumps the blood out to the body. The unit of measurement is millimeters of mercury (mm Hg). Pulse is the number of times your heart beats per minute. The unit of measurement is beats per minute (BPM). These test measurements compared in adults with moderate to severe plaque psoriasis week 16 after 16 weeks adalimumab and week 28 after 16 weeks adalimumab plus 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg vitamin B12. (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Systolic BP increased | Systolic BP unchanged | Systolic BP decreased | Diastolic BP increased | Diastolic BP unchanged | Diastolic BP decreased | Pulse increased | Pulse unchanged | Pulse decreased | |
| Humira Then Humira Plus 3 B Vitamins | 4 | 0 | 3 | 5 | 0 | 2 | 5 | 0 | 2 |
Serum homocysteine measured at week 16 after 16 weeks of adalimumab and week 28 after 16 weeks of adalimumaband then 12 weeks of adalimumab plus 5 mg folic acid, 100mg B6 and 1000 mcg of B12 in adults ages 18-65 with moderate to sever plaque psoriasis.. (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Increased | Unchanged | Decreased | |
| Humira Plus 3 B Vitamins | 1 | 0 | 3 |
Serum magnesium (Mg) was to be measured at baseline, Week 16 (on adalimumab) and at week 28 (on adalimumab plus folic acid, vitamins B6 and B12) in adult participants age 18 or older with moderate to severe plaque psoriasis. (NCT01704599)
Timeframe: Weeks 16 and 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Increased | Unchanged | Decreased | |
| Humira Then Humira Plus 3 B Vitamins | 1 | 2 | 2 |
Serum phosphorus (P) levels were to be measured weeks16 and 28 in adult participants age 18 and older with moderate to severe plaque psoriasis at week 0 on no systemic psoriasis medication; week 16 after 16 weeks of adalimumab and at week 28 after 16 weeks of adalimumab plus 12 weeks of adalimumab plus 5 mg folic acid, 100 mg vitamin B6 and 1000 mcg of B12. (NCT01704599)
Timeframe: Week 16 then Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Increased | Unchanged | Decreased | |
| Humira Then Humira Plus 3 B Vitamins | 3 | 0 | 2 |
Serum vitamin B6 levels were to be measured weeks16 after 16 weeks adalimumab and at week 28 after 16 weeks adalimumab and 12 weeks on adalimuamb, folic acid 5 mg, b6 100 mg and B12 1000 mcg in adult participants with moderate to sever plque psoriasis. (NCT01704599)
Timeframe: At Week 16 and Week 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Increased | Unchanged | Decreased | |
| Humira Then Humira Plus 3 B Vitamins | 4 | 0 | 0 |
Women of childbearing years over age 18 with moderate to severe plaque psoriasis on no systemic therapy at week 0 of study. (NCT01704599)
Timeframe: At screening
| Intervention | participant (Number) | |
|---|---|---|
| Negative | Positive | |
| Humira Then Humira Plus 3 B Vitamins | 1 | 0 |
PASI: formula based on body surface areas on head/neck, trunk, both arms & legs with disease quality grading induration, scale and erythema on participants ages 18-65 with moderate to severe plaque psoriasis measured at weeks 16 and 28. (NCT01704599)
Timeframe: Weeks 16 and 28
| Intervention | participants (Number) | ||
|---|---|---|---|
| Improved | Unchanged | Worsened | |
| Humira Then Humira Plus 3 B Vitamins | 4 | 1 | 2 |
Baseline VEGF level at week zero related to PASI change Week 16 on adalimumab compared to Week 28 after additonal 12 weeks of adalimumab plus folic acid, vitamin B6 and B12 in adult psoriasis patients ages 18-65 with moderate to severe plaque psoriasis.High levels were greater than or equal to 140 pg/ml. Normal VEGF was below this level. (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| PASI improved with high VEGF | PASI Worsened with high VEGF | PASI Unchanged with normal VEGF | PASI Improved with normal VEGF | PASI Worsened with normal VEGF | |
| Humira Then Humira Plus 3 B Vitamins | 1 | 2 | 1 | 3 | 0 |
Change in PASI from Week 16 on adalimumab to Week 28 on adalimumab, folic acid, vitamin B6 and B12 in adults ages 18-65 with moderate to severe plaque psoriasis. (NCT01704599)
Timeframe: Week 16 and Week 28
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| BMI >27.3 who improved | BMI >27.3 who worsened | BMI of 27.3 who were unchanged | BMI<27.3 who improved | BMI<27.3 who worsened | |
| Humira Then Humira Plus 3 B Vitamins | 4 | 0 | 0 | 0 | 2 |
Change in PASI from Week 16 after 16 weeks of adalimumab to Week 28 after another 12 weeks of adalimumab plus folic acid, vitamins B6 and B12 and Change reported by telephone 70 days after week 28 (NCT01704599)
Timeframe: Week 16 to Week 28 and Week 28 to post study day 70
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| high titer worsened | high titer improved then worsened day 70 | normal titer improved | normal titer unchanged then improved day 70 | normal titer worsened | |
| Humira Then Humira Plus 3 B Vitamins | 1 | 1 | 3 | 1 | 1 |
"The patients were randomly assigned oral betaine or placebo for 2 months, followed by a 2 month washout. Each patient then received the alternate study medication for 2 months.~Urinary Oxalate Excretion was measured by oxalate oxidase. Two 24 hour urine collections were obtained at baseline, and during the eighth week of each study period." (NCT00283387)
Timeframe: baseline, 2 months, 6 months
| Intervention | umol/mg (Mean) |
|---|---|
| Betaine | 1.43 |
| Placebo | 1.04 |
20 reviews available for pyridoxine and Hyperhomocysteinemia
| Article | Year |
|---|---|
Pharmacotherapy of hyperhomocysteinaemia in patients with thrombophilia.
Topics: Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Methionine; Pyridoxine; Renal Insufficiency; | 2002 |
Hyperhomocysteinemia and transplant coronary artery disease.
Topics: Animals; Coronary Disease; Folic Acid; Heart Transplantation; Homocysteine; Humans; Hyperhomocystein | 2002 |
Does homocysteine cause hypertension?
Topics: Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Hypertension; Metabolic Syndrome; Pyridoxine | 2003 |
Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease.
Topics: Cardiovascular Diseases; Dietary Supplements; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia | 1998 |
Hyperhomocysteinemia, atherosclerosis and thrombosis.
Topics: Adult; Aged; Animals; Arteriosclerosis; Avitaminosis; Case-Control Studies; Clinical Trials as Topic | 1999 |
[Hyperhomocysteinemia as a risk factor for venous thrombosis].
Topics: Adult; Aged; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Male; Middle Aged; Pros | 1999 |
Homocysteine and the heart.
Topics: Adult; Coronary Disease; Folic Acid; Humans; Hyperhomocysteinemia; Male; Pyridoxine; Risk Factors | 1999 |
[Homocysteinemia and vascular disease--a new risk factor is born].
Topics: Arteriosclerosis; Cardiovascular Diseases; Folic Acid; Humans; Hyperhomocysteinemia; Pyridoxine; Ris | 1999 |
[Homocysteine and cardiovascular risk].
Topics: Arteriosclerosis; Cardiovascular Diseases; Folic Acid; Homocystinuria; Humans; Hyperhomocysteinemia; | 1999 |
[Hyperhomocysteinemia: a risk factor for arterial and venous thrombosis].
Topics: Arteriosclerosis; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Pyridoxine; Risk Factors; | 1999 |
[Hyperhomocysteinemia, a risk factor for atherosclerosis: causes and effects].
Topics: Age Factors; Arterial Occlusive Diseases; Arteriosclerosis; Cerebrovascular Disorders; Coronary Dise | 1999 |
Hyperhomocysteinemia in organ transplantation.
Topics: Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Organ Transplantation; Polymorphism, Genetic | 2000 |
Preventive health care, 2000 update: screening and management of hyperhomocysteinemia for the prevention of coronary artery disease events. The Canadian Task Force on Preventive Health Care.
Topics: Aged; Arteriosclerosis; Canada; Coronary Disease; Dietary Supplements; Disease Susceptibility; Fasti | 2000 |
Homocysteine--relevant for atherogenesis?
Topics: Arteriosclerosis; Case-Control Studies; Coronary Disease; Folic Acid; Hematinics; Humans; Hyperhomoc | 2000 |
Mild hyperhomocysteinemia is an independent risk factor of arterial vascular disease.
Topics: Arteriosclerosis; Case-Control Studies; Clinical Trials as Topic; Comorbidity; Coronary Disease; Fol | 2000 |
Homocysteine and renal disease.
Topics: Adult; Arteriosclerosis; Cardiovascular Diseases; Case-Control Studies; Child; Endothelium, Vascular | 2000 |
Vascular complications of severe hyperhomocysteinemia in patients with homocystinuria due to cystathionine beta-synthase deficiency: effects of homocysteine-lowering therapy.
Topics: Adolescent; Adult; Aged; Australia; Child; Child, Preschool; Cohort Studies; Cystine; Drug Resistanc | 2000 |
Homocysteine and neurologic disease.
Topics: Brain Diseases; Epilepsy; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Neurodegenerative | 2000 |
Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease.
Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Folic Acid; Homocysteine; Humans; Hyperh | 2000 |
Does lowering plasma homocysteine reduce vascular disease risk?
Topics: Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Pyridoxine; Risk Factors; Vascular Diseases | 2001 |
19 trials available for pyridoxine and Hyperhomocysteinemia
| Article | Year |
|---|---|
Vitamin supplementation reduces the progression of atherosclerosis in hyperhomocysteinemic renal-transplant recipients.
Topics: Adult; Arteriosclerosis; Carotid Arteries; Dietary Supplements; Double-Blind Method; Female; Folic A | 2003 |
Hyperhomocysteinaemia is not associated with increased levels of asymmetric dimethylarginine in patients with ischaemic heart disease.
Topics: Adult; Arginine; Female; Folic Acid; Humans; Hyperhomocysteinemia; Male; Middle Aged; Myocardial Isc | 2003 |
Plasma homocysteine and markers for oxidative stress and inflammation in patients with coronary artery disease--a prospective randomized study of vitamin supplementation.
Topics: Aged; Biomarkers; Coronary Artery Disease; Female; Folic Acid; Homocysteine; Humans; Hyperhomocystei | 2005 |
Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia.
Topics: Adult; Chronic Disease; Cross-Over Studies; Double-Blind Method; Female; Folic Acid; Homocysteine; H | 2006 |
No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk.
Topics: Adolescent; Adult; Arginine; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Do | 2006 |
Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Folic Acid; | 2007 |
Randomized clinical trial of homocysteine level lowering therapy and fractures.
Topics: Aged; Cardiovascular Diseases; Drug Therapy, Combination; Female; Folic Acid; Fractures, Bone; Homoc | 2007 |
Plasma total homocysteine response to oral doses of folic acid and pyridoxine hydrochloride (vitamin B6) in healthy individuals. Oral doses of vitamin B6 reduce concentrations of serum folate.
Topics: Administration, Oral; Adult; Cholesterol; Cysteine; Dipeptides; Female; Folic Acid; Homocysteine; Hu | 1999 |
Serum homocysteine increases after therapy with fenofibrate or bezafibrate.
Topics: Adult; Bezafibrate; Chromatography, High Pressure Liquid; Fenofibrate; Folic Acid; Hematinics; Homoc | 1999 |
Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy.
Topics: Adult; Aged; Erythrocytes; Female; Humans; Hyperhomocysteinemia; Injections, Intravenous; Kidney Fai | 1999 |
Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial.
Topics: Blood Pressure; Coronary Artery Disease; Family; Female; Folic Acid; Hematinics; Humans; Hyperhomocy | 2000 |
Homocysteine and venous thrombosis: outline of a vitamin intervention trial.
Topics: Adult; Aged; Aged, 80 and over; Comorbidity; Double-Blind Method; Female; Folic Acid; Follow-Up Stud | 2000 |
Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients.
Topics: Double-Blind Method; Drug Administration Schedule; Erythrocytes; Female; Folic Acid; Genotype; Homoc | 2001 |
Homocysteine lowering effect of different multivitamin preparations in patients with end-stage renal disease.
Topics: Dietary Supplements; Dose-Response Relationship, Drug; Female; Folic Acid; Homocysteine; Humans; Hyp | 2001 |
Homocysteine--a treatable risk factor for allograft vascular disease after heart transplantation?
Topics: Aged; Cohort Studies; Cyclosporine; Dietary Supplements; Female; Folic Acid; Folic Acid Deficiency; | 2001 |
An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease.
Topics: Body Mass Index; Cardiovascular Diseases; Cross-Sectional Studies; Ethnicity; Female; Folic Acid; Ge | 2001 |
Long-term homocysteine-lowering treatment with folic acid plus pyridoxine is associated with decreased blood pressure but not with improved brachial artery endothelium-dependent vasodilation or carotid artery stiffness: a 2-year, randomized, placebo-contr
Topics: Adult; Blood Pressure; Brachial Artery; Carotid Arteries; Drug Therapy, Combination; Elasticity; End | 2001 |
Decreased rate of coronary restenosis after lowering of plasma homocysteine levels.
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis; Coronary Stenosis; Corona | 2001 |
Betaine supplementation decreases post-methionine hyperhomocysteinemia in chronic renal failure.
Topics: Aged; Betaine; Cross-Over Studies; Drug Therapy, Combination; Fasting; Female; Folic Acid; Hematinic | 2002 |
34 other studies available for pyridoxine and Hyperhomocysteinemia
| Article | Year |
|---|---|
Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran.
Topics: Clinical Trials as Topic; Cystathionine beta-Synthase; Folic Acid; Heme; Homocysteine; Humans; Hyper | 2022 |
Oral exposure to the anti-pyridoxine compound 1-amino D-proline further perturbs homocysteine metabolism through the transsulfuration pathway in moderately vitamin B₆ deficient rats.
Topics: Animals; Asymptomatic Diseases; Biomarkers; Cystathionine; Cystathionine gamma-Lyase; Diet; Disease | 2015 |
Drug-induced pertubation of the aminothiol redox-status in patients with epilepsy: improvement by B-vitamins.
Topics: Adult; Anticonvulsants; Carbamazepine; Case-Control Studies; Cysteine; Dipeptides; Drug Evaluation; | 2008 |
Recurrent postpartum cerebral sinus vein thrombosis as a presentation of cystathionine-beta-synthase deficiency.
Topics: Adult; Anticoagulants; Anticonvulsants; Epilepsy; Female; Folic Acid; Homocystinuria; Humans; Hyperh | 2010 |
[Hyperhomocysteinemia, coagulation disorders, inflammations: new risk factors for stroke].
Topics: Adult; Blood Coagulation Disorders; C-Reactive Protein; Female; Folic Acid; Humans; Hyperhomocystein | 2002 |
Intravenous treatment of hyperhomocysteinemia in patients on chronic hemodialysis--a pilot study.
Topics: Aged; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Dru | 2004 |
Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study.
Topics: Adult; Cause of Death; Double-Blind Method; Folic Acid; Homocysteine; Hospitals, Veterans; Humans; H | 2004 |
Do you need this heart disease test?
Topics: Cardiovascular Diseases; Folic Acid; Heart Diseases; Humans; Hyperhomocysteinemia; Nutrition Policy; | 1999 |
Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis.
Topics: Creatinine; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Kidney Failure, Chronic; Periton | 1999 |
Combination of low-dose folic acid and pyridoxine for treatment of hyperhomocysteinaemia in patients with premature arterial disease and their relatives.
Topics: Adult; Age of Onset; Arteriosclerosis; Drug Therapy, Combination; Female; Folic Acid; Homocysteine; | 1999 |
Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS)
Topics: Adult; Aged; Amino Acid Substitution; Arteriosclerosis; Carotid Arteries; Carotid Stenosis; Comorbid | 1999 |
Determinants of fasting and post-methionine homocysteine levels in families predisposed to hyperhomocysteinemia and premature vascular disease.
Topics: Adult; Age Factors; Amino Acid Substitution; Arteriosclerosis; Body Mass Index; Comorbidity; Fasting | 1999 |
[Obstetric problems followed by stroke].
Topics: Abortion, Habitual; Adult; Arteriosclerosis; Cerebral Infarction; Diagnosis, Differential; Female; F | 1999 |
Hyperhomocyst(e)inemia--determining factors and treatment.
Topics: Animals; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Cricetinae; Female; F | 1999 |
Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease. A prospective cohort study.
Topics: Adult; Age of Onset; Aged; Arterial Occlusive Diseases; Cardiovascular Diseases; Female; Folic Acid; | 1999 |
[Atherosclerosis. Congress of the European Atherosclerosis Society (EAS), Athens (Greece), 26-29 May 1999].
Topics: Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Ascorbic Acid; Cholesterol, LDL; Diet; Eur | 1999 |
Treatment of hyperhomocysteinemia with folic acid and vitamins B12 and B6 attenuates thrombin generation.
Topics: Adult; Cysteine; Female; Folic Acid; Hematinics; Humans; Hyperhomocysteinemia; Male; Middle Aged; Py | 1999 |
Extracellular magnesium regulates effects of vitamin B6, B12 and folate on homocysteinemia-induced depletion of intracellular free magnesium ions in canine cerebral vascular smooth muscle cells: possible relationship to [Ca2+]i, atherogenesis and stroke.
Topics: Animals; Arteriosclerosis; Basilar Artery; Calcium; Cells, Cultured; Cerebral Arteries; Dogs; Folic | 1999 |
Three months supplementation of hyperhomocysteinaemic patients with folic acid and vitamin B6 improves biological markers of endothelial dysfunction.
Topics: Adult; Endothelium, Vascular; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteinemia; Male; | 1999 |
Effect of short-term vitamin (folic acid, vitamins B6 and B12) administration on endothelial dysfunction induced by post-methionine load hyperhomocysteinemia.
Topics: Administration, Oral; Adult; Blood Flow Velocity; Drug Therapy, Combination; Endothelium, Vascular; | 1999 |
Endpoints for homocysteine-lowering trials.
Topics: Adult; Aged; Child; Coronary Artery Disease; Folic Acid; Hematinics; Humans; Hyperhomocysteinemia; P | 2000 |
Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature atherothrombotic cerebrovascular disease. A prospective cohort study.
Topics: Adult; Arteriosclerosis; Female; Folic Acid; Follow-Up Studies; Hematinics; Humans; Hyperhomocystein | 2000 |
Effect of chronic alcohol consumption on total plasma homocysteine level in rats.
Topics: Alcohol Drinking; Animals; Folic Acid; Hematinics; Homocysteine; Hyperhomocysteinemia; Male; Pyridox | 2000 |
Children with stroke: polymorphism of the MTHFR gene, mild hyperhomocysteinemia, and vitamin status.
Topics: Adolescent; Case-Control Studies; Child; Child, Preschool; Cytosine; Female; Folic Acid; Genetic Pre | 2000 |
The effect of different treatment regimens in reducing fasting and postmethionine-load homocysteine concentrations.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Chromatography, High Pressure Liquid; Drug The | 2000 |
[Homocysteine and its metabolites in chronic renal insufficiency and the effect of a vitamin replacement].
Topics: Adult; Aged; Arteriosclerosis; Cysteine; Female; Folic Acid; Homocysteine; Humans; Hyperhomocysteine | 2000 |
Is there a role of cyclosporine A on total homocysteine export from human renal proximal tubular epithelial cells?
Topics: Biological Transport, Active; Cells, Cultured; Cyclosporine; Epithelial Cells; Folic Acid; Homocyste | 2001 |
Supplementation of atherogenic diet with B vitamins does not prevent atherosclerosis or vascular dysfunction in monkeys.
Topics: Animals; Arteriosclerosis; Blood Coagulation; Carotid Arteries; Cholesterol; Diet, Atherogenic; Diet | 2001 |
Effects of methionine loading on plasma and erythrocyte sulphur amino acids and sulph-hydryls before and after co-factor supplementation in haemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Amino Acids, Sulfur; Case-Control Studies; Erythrocytes; Female; Fol | 2001 |
Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Cells, Cultured; Diet; Disease Models, Animal; Folic A | 2001 |
Effective treatment of hyperhomocysteinemia in heart transplant recipients with and without renal failure.
Topics: Adult; Algorithms; Creatinine; Female; Folic Acid; Heart Transplantation; Humans; Hyperhomocysteinem | 2001 |
Anti-epileptic drug treatment in children: hyperhomocysteinaemia, B-vitamins and the 677C-->T mutation of the methylenetetrahydrofolate reductase gene.
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Folic Acid; Genotype; Homocyste | 2000 |
Influence of vitamin-optimized plasma homocysteine cutoff values on the prevalence of hyperhomocysteinemia in healthy adults.
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Female; Folic Acid; Homocysteine; Humans; Hyperhom | 2001 |
Dimethylglycine accumulates in uremia and predicts elevated plasma homocysteine concentrations.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Betaine; Betaine-Homocysteine S-Methyltransferase; | 2001 |